Peptide Cycling Protocols for Optimal Results

How goal-based cycles are described

Most peptide cycling advice online is organized by goal. A forum guide or vendor page picks a target, such as adding muscle or losing fat, names a few compounds for it, and gives a length for the "on" period.

Very little of it has been tested. As of October 2026, no human trial has compared one goal-based cycle with another, or with steady use, and most of the compounds involved have no outcome trial at all. This page takes the common goal-based cycles one at a time and sets each beside the best evidence we could find. Why people cycle in the first place, mostly concern about receptor desensitization, is covered in our explainer on receptor science and cycling. The debate between long on/off blocks and weekly breaks has its own page on cycling philosophies in bodybuilding.

Mass-gain cycles

The usual "mass" cycle in community and vendor guides pairs CJC-1295 with DAC and GHRP-2 or GHRP-6. Vendor and community guidance for CJC-1295 lists 500-1000 mcg per week in one or two injections over 12-16 weeks; we couldn't trace that range to a trial. Guides for GHRP-2 and GHRP-6 list 100-300 mcg per injection, one to three times a day, usually for 8-16 weeks. Users often pick GHRP-6 for a bulk because of the strong hunger it causes, which they report within about half an hour of an injection.

The usual rationale is that CJC-1295 with DAC produces a constant "bleed" of growth hormone (GH). The human data don't support that description. In a 2006 study of healthy men aged 20-40, one injection of 60 or 90 mcg/kg raised trough GH about 7.5-fold and mean GH by 46%, but the frequency and size of the GH pulses didn't change. GH kept its pulsatile pattern, sitting on a higher baseline. An earlier 2006 study in healthy adults found that single doses raised GH 2-10 times for six days or more and IGF-1 1.5-3 times for 9-11 days.

No study has shown that any of this builds muscle. FDA's 2024 review of CJC-1295 found no published data on its effectiveness in people. The closest long-term data come from a different GH secretagogue, oral MK-677. In a trial of 25 mg daily in 65 healthy adults aged 60-81, fat-free mass rose about 1.1 kg after a year while it fell about 0.5 kg on placebo. Strength and function didn't change. Fasting glucose rose and insulin sensitivity fell. Fat-free mass includes water, and water retention is one of the most common things users report on GH peptides, so a gain on the scale during a mass cycle is hard to interpret.

Fat-loss cycles

Fat-loss cycles in user guides usually switch to shorter-acting compounds: Mod GRF 1-29 (CJC-1295 without DAC) with ipamorelin, often for 8-12 weeks. Vendor guidance for ipamorelin lists 200-300 mcg two or three times a day, while many users describe a single bedtime dose of 100-300 mcg of each. Some guides add AOD-9604, which forum users most often describe as 300 mcg by subcutaneous injection each morning for about 12 weeks.

No GH secretagogue has a fat-loss trial. The MK-677 study above measured abdominal visceral fat and total fat mass and found no difference from placebo. Ipamorelin's reputation as the "cleanest" GHRP comes mostly from vendor copy, which says it raises GH with little effect on cortisol or prolactin. Its only efficacy trial was a Phase 2 study of intravenous ipamorelin in 117 adults recovering from abdominal surgery, and it missed its primary endpoint. FDA advisers reviewing it in 2024 heard that the ipamorelin group had more low potassium and high blood sugar than the placebo group, along with more insomnia. FDA also cites deaths in that study, with causality unclear. "Minimal side effects" claims more than the data show.

AOD-9604 has the clearest negative result of any compound in these cycles. The OPTIONS trial enrolled 536 adults with obesity and gave them oral AOD-9604 (0.25, 0.5 or 1 mg daily) or placebo for 24 weeks alongside diet and exercise. Weight loss at 12 weeks, the primary endpoint, wasn't significantly different from placebo, and the company stopped developing it for obesity. FDA's 2024 review found no human data at all for AOD-9604 given by subcutaneous injection, which is how users take it. In forum reports, most users describe noticing little or nothing.

Where GLP-1 medicines fit

Fat-loss cycles are sometimes compared with semaglutide (Wegovy) and tirzepatide (Zepbound). Those are prescription medicines, and they're used continuously as their labels describe, not cycled. Two withdrawal trials show what happens when they stop. In STEP 4, adults who reached the 2.4 mg weekly dose of semaglutide during a 20-week run-in were randomized to continue or switch to placebo. Over the next 48 weeks, the semaglutide group lost another 7.9% of body weight while the placebo group regained 6.9%. SURMOUNT-4 found the same pattern with tirzepatide: after 36 weeks at 10 or 15 mg weekly, people switched to placebo regained 14.0% over a year, while those who continued lost another 5.5%.

Research-use vials sold online under these drug names aren't the approved products. They aren't made under the same controls, and none of these trial results applies to them.

Recovery cycles

Recovery blocks usually pair BPC-157 with TB-500. Users commonly report 250-500 mcg of BPC-157 a day by subcutaneous injection, and the 4-12 week duration comes from vendor and community guidance. For TB-500, vendor guidance describes 2-2.5 mg twice a week for 4-6 weeks, then monthly doses, while forum users describe a wider spread, up to 2-5 mg twice weekly. Guides often place these in the "off" weeks of a GH peptide cycle. The reasoning is that neither acts on the growth hormone secretagogue receptor, so that receptor gets a break while the user keeps working on an injury.

The evidence is thin for each compound and missing for the pairing. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies, 35 of them preclinical, and found no clinical safety data. For the TB-500 fragment, FDA says it has not identified any human exposure data. No controlled study has tested the two together. Nobody has tested whether a recovery block during a GH break changes the next GH cycle, either.

The kitchen-sink problem

Community threads often describe something other than a single goal-based cycle: several at once. A typical example stacks a GH peptide pair on top of BPC-157 and TB-500. AOD-9604 often gets added for fat loss, sometimes with melanotan II for tanning, and all of it starts in the same month. This causes problems that have nothing to do with receptors.

The first is that it becomes impossible to tell what did anything. If a sore shoulder improves, there's no way to tell whether BPC-157 helped or the shoulder would have recovered with rest anyway. Most of these compounds have no controlled trial, so a user's own before-and-after is often the only feedback available, and running everything at once erases it.

Side effects also overlap. Water retention and numb or tingling hands are common in user reports for CJC-1295 and ipamorelin alike, and GHRP-2 users describe the same thing, so a problem can't be traced to one compound. The GH-raising compounds share a cost to glucose control as well: MK-677 lowered insulin sensitivity in its trial, and FDA's safety listings cite raised blood glucose for GHRP-6. Goals can pull against each other too. GHRP-6's hunger may suit a bulk, but it works against a fat-loss goal pursued at the same time.

Every added vial is also another product of uncertain quality. Gray-market peptides aren't made under drug manufacturing controls, so five compounds means five separate chances of a mislabeled or contaminated vial.

Some combinations do come with a stated rationale, the main one being a GHRH analog paired with a GHRP. That reasoning, and how little has tested it, is covered in our guide to peptide stacking.

What we still don't know

The biggest gap is any trial of cycling itself. The one long human study of a GHRP's effect over time gave twice-daily hexarelin to 12 healthy older adults for 16 weeks. The GH response fell partway and recovered after four weeks off. That fits the idea behind breaks, but it measured GH rather than muscle or fat, and nobody has repeated it with the compounds in today's goal-based cycles.

Long-term safety of running several compounds for months at a time is also unstudied. Evidence on years of secretagogue use, including what happens to IGF-1, is collected in our page on peptides and long-term effects.